Vistagen Therapeutics, Inc. (VTGN) - Dilution Analysis

10-Q filing | 35.7M shares outstanding

10-Q filing | 31.9M shares outstanding

10-K filing | 30.9M shares outstanding

8-K filing: The company filed a prospectus supplement relating to the offer and sale of common stock with an aggregate offering price of up to $175,000,000. As of the date of the Prospectus Supplement, the Company had issued and sold 1,273,883 shares of its Common Stock pursuant to the Sales Agreement and the Prior Prospectus Supplement and accompanying base prospectus for aggregate gross sale proceeds of approximately $3,443,612. ($3.44M proceeds)

10-Q filing | 30.7M shares outstanding

10-Q filing | 27.8M shares outstanding

10-Q filing | 27.1M shares outstanding

10-K filing | 27.0M shares outstanding

10-Q filing | 29.4M shares outstanding

S-3 filing: The company may offer and sell securities from time to time in one or more offerings of up to $350,000,000 in aggregate offering price.

10-Q filing | 27.0M shares outstanding

8-K filing: Vistagen Therapeutics, Inc. closed an underwritten offering of 15,010,810 shares of common stock, pre-funded warrants to purchase 3,577,240 shares, warrants to purchase 9,294,022 shares (T1 Warrants), and warrants to purchase 11,265,086 shares (T2 Warrants) at a combined price of $5.38 per share/warrant combination, resulting in net proceeds of approximately $93.5 million.

10-Q filing | 9.4M shares outstanding

10-K filing | 7.9M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 206,838,084 → 6,887,708

S-3/A filing: This is an S-3/A filing for a shelf offering of common stock. The filing registers 12,193,069 shares of common stock for sale by selling stockholders. A law firm partner owns 150,583 shares of the company's common stock.

S-3 filing: This is an S-3 filing for a shelf offering of common stock.

10-Q filing | 206.8M shares outstanding

8-K filing: Vistagen Therapeutics, Inc. completed its acquisition of Pherin Pharmaceuticals, Inc. on February 2, 2023, issuing 12,410,181 unregistered shares of Company Common Stock to Pherin stockholders and $125,800 in cash to other Pherin stockholders.

8-K filing: Vistagen Therapeutics, Inc. entered into an Agreement and Plan of Merger with Pherin Pharmaceuticals, Inc., acquiring Pherin through a merger of a wholly-owned subsidiary, with Vistagen issuing 12,410,181 unregistered shares of its common stock to Pherin stockholders.

10-Q filing | 206.8M shares outstanding

10-Q filing | 206.6M shares outstanding

10-K filing | 198.0M shares outstanding

10-Q filing | 206.5M shares outstanding

10-Q filing | 199.7M shares outstanding

10-Q filing | 192.9M shares outstanding

10-K filing | 191.4M shares outstanding

S-3 filing: The registration statement is for an indeterminate number of shares of common stock, preferred stock, warrants, and units with an aggregate initial offering price not to exceed $250,000,000.

10-Q filing | 141.7M shares outstanding

10-Q filing | 74.0M shares outstanding

10-Q filing | 74.0M shares outstanding

10-K filing | 55.8M shares outstanding

S-3/A filing: This S-3/A filing registers shares of common stock offered by selling stockholders, including shares issuable upon exercise of warrants.

S-3 filing: This is an S-3 filing for shares of common stock offered by selling stockholders, including shares issuable upon exercise of warrants.

S-1/A filing: This S-1/A filing includes information about a registered direct offering and concurrent offering of warrants from January 2020, as well as a purchase agreement with Lincoln Park for up to $10,250,000 of common stock.

S-1 filing: This S-1 filing registers shares related to a purchase agreement with Lincoln Park for up to $10.25 million of common stock, and also discusses a January 2020 registered direct offering and concurrent offering of warrants.

10-Q filing | 48.0M shares outstanding